Device Trial Radar · NCT04326946
International Alfapump Cohort Study
Last checked: Nov 19, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Aug 14, 2018
Primary completion
Dec 31, 2028
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Sequana Medical N.V.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 30, 2020
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes
Summary
As written by the sponsor on the registry.
This Registry is designed to follow patients who have been implanted with an alfapump system, which is a newly marketed product from Sequana Medical AG, a Swiss Medical Device company.
Conditions
- Liver Cirrhoses
- Malignant Ascites
Interventions
AlfapumpDevice
alfapump implementation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient survival at 6 months post implantTime frame: 6 months post-implant
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Universitätsklinikum Leipzig
Leipzig, Germany
Inselspital
Bern, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.